Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

Core Insights - Rigel Pharmaceuticals presented data on REZLIDHIA® (olutasidenib) at the 2024 ASCO Annual Meeting, highlighting its long-term efficacy in treating relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML) patients, including those previously treated with venetoclax [1][2][4] - The data showed that olutasidenib achieved a complete remission (CR) or CR with partial hematologic recovery (CRh) in 35% of efficacy evaluable patients, with a median duration of CR/CRh of 25.3 months [4] - The ongoing Phase 1b trial of R289, a dual inhibitor of IRAK1 and IRAK4, is also being presented, targeting lower-risk myelodysplastic syndrome (LR-MDS) patients [2][8] Group 1: REZLIDHIA® Efficacy and Safety - The five-year results from the Phase 2 trial of olutasidenib demonstrated durable responses in heavily pretreated patients with mIDH1 AML, with an overall response rate of 48% and median overall survival of 11.6 months [4][5] - In a subgroup analysis of elderly patients aged 75 and older, 31% achieved CR/CRh, with a median duration of 25.9 months [5][6] - Among patients who were R/R to prior venetoclax, 33% achieved CR/CRh, with a median overall survival of 16.2 months [4] Group 2: R289 Trial Overview - R289 is being evaluated in a Phase 1b trial for patients with LR-MDS, an area identified as having high unmet medical needs [2][8] - The trial aims to assess the safety and preliminary efficacy of R289, with multiple dose levels already completed and active recruitment ongoing [11][12] - R289 is a prodrug of R835, which has shown potential in blocking inflammatory cytokine production linked to persistent cytopenias in lower-risk MDS patients [8]